Leonard M Blum
CIK 1222247 · See Remarks · last filed 2018-05-16
Leonard M Blum is a corporate insider who has filed 33 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for EYPT, was dated May 16, 2018. Across all open-market trades the lifetime net is +$440.7K, making them a net buyer over the disclosed history. 28 SEC filings were submitted jointly with Innoviva, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
THRX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EYPT | See Remarks | — | $0.40 | — | $0 | 1 | 2018-05-16 |
| Theravance Biopharma, Inc. (TBPH) Delisted | Sr VP, Chief Comm. Officer | 182,731 | $17.03 | $3.11M | $0 | 7 | 2016-02-23 |
| Innoviva, Inc. (THRX) Delisted | Sr VP, Chief Comm. Officer | 401,538 | $4.06 | $1.63M | $440.7K | 23 | 2014-08-22 |
| ICOS CORP (ICOS) Delisted | Senior VP, Sales and Marketing | 0 | — | — | $0 | 2 | 2007-01-30 |
Recent Filings
33 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-05-16 | EYPT | Grant (A) | — | $0 | EDGAR |
| 2016-02-23 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −16,101 | -$252.0K | EDGAR |
| 2015-08-24 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −934 | -$12.1K | EDGAR |
| 2015-06-04 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −7,360 | -$101.8K | EDGAR |
| 2015-05-22 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −673 | -$9.6K | EDGAR |
| 2015-02-24 | Theravance Biopharma, Inc. (TBPH) Delisted | Tax (F) | −674 | -$13.2K | EDGAR |
| 2015-02-09 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | +90,000 | $0 | EDGAR |
| 2014-10-10 | Theravance Biopharma, Inc. (TBPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-08-22 | Innoviva, Inc. (THRX) Delisted | Tax (F) | −3,261 | -$74.2K | EDGAR |
| 2014-02-24 | Innoviva, Inc. (THRX) Delisted | Tax (F) | −4,311 | -$172.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.